Diabetologia

, Volume 61, Issue 2, pp 413–423 | Cite as

GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study

  • Lærke S. Gasbjerg
  • Mikkel B. Christensen
  • Bolette Hartmann
  • Amalie R. Lanng
  • Alexander H. Sparre-Ulrich
  • Maria B. N. Gabe
  • Flemming Dela
  • Tina Vilsbøll
  • Jens J. Holst
  • Mette M. Rosenkilde
  • Filip K. Knop
Article

Abstract

Aims/hypothesis

Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone secreted postprandially from enteroendocrine K cells, but despite therapeutically interesting effects, GIP physiology in humans remains incompletely understood. Progress in this field could be facilitated by a suitable GIP receptor antagonist. For the first time in humans, we investigated the antagonistic properties of the naturally occurring GIP(3-30)NH2 in in vivo and in in vitro receptor studies.

Methods

In transiently transfected COS-7 cells, GIP(3-30)NH2 was evaluated with homologous receptor binding and receptor activation (cAMP accumulation) studies at the glucagon-like peptide 1 (GLP-1), glucagon-like peptide-2 (GLP-2), glucagon, secretin and growth hormone-releasing hormone (GHRH) receptors. Ten healthy men (eligibility criteria: age 20–30 years, HbA1c less than 6.5% [48 mmol/mol] and fasting plasma glucose [FPG] less than 7 mmol/l) were included in the clinical study. Data were collected as plasma and serum samples from a cubital vein cannula. As primary outcome, insulin secretion and glucose requirements were evaluated together with in a randomised, four-period, crossover design by infusing GIP(3-30)NH2 (800 pmol kg−1 min−1), GIP (1.5 pmol kg−1 min−1), a combination of these or placebo during hyperglycaemic clamp experiments. The content of the infusions were blinded to the study participants and experimental personnel. No study participants dropped out.

Results

GIP(3-30)NH2 neither bound, stimulated nor antagonised a series of related receptors in vitro. The elimination plasma half-life of GIP(3-30)NH2 in humans was 7.6 ± 1.4 min. Markedly larger amounts of glucose were required to maintain the clamp during GIP infusion compared with the other days. GIP-induced insulin secretion was reduced by 82% (p < 0.0001) during co-infusion with GIP(3-30)NH2, and the need for glucose was reduced to placebo levels. There were no effects of GIP(3-30)NH2 alone or of GIP with or without GIP(3-30)NH2 on plasma glucagon, GLP-1, somatostatin, triacylglycerols, cholesterol, glycerol or NEFA. GIP(3-30)NH2 administration was well tolerated and without side effects.

Conclusions/interpretation

We conclude that GIP(3-30)NH2 is an efficacious and specific GIP receptor antagonist in humans suitable for studies of GIP physiology and pathophysiology.

Trial registration

ClinicalTrials.gov registration no. NCT02747472.

Funding

The study was funded by Gangstedfonden, the European Foundation for the Study of Diabetes, and Aase og Ejnar Danielsens fond.

Keywords

Class B G protein-coupled receptor (GPCR) Glucose-dependent insulinotropic polypeptide (GIP) Hyperglycaemic clamp Incretin physiology Insulin secretion in vivo Pharmacology 

Abbreviations

DPP-4

Dipeptidyl peptidase 4

FPG

Fasting plasma glucose

GHRH

Growth hormone-releasing hormone

GIP

Glucose-dependent insulinotropic polypeptide

GLP-1

Glucagon-like peptide-1

GLP-2

Glucagon-like peptide-2

GPCR

G protein-coupled receptor

iAUC

Incremental AUC

ISR

Insulin secretion rate

PC

Prohormone convertase

Notes

Acknowledgements

The authors sincerely thank the study participants for their dedication. We thank S. M. Schmidt (Center for Diabetes Research, Gentofte Hospital, Denmark) and I. A. Nachar (Center for Diabetes Research, Gentofte Hospital, Denmark) for laboratory assistance during the clinical study. In addition, the authors thank L. B. Albæk (Department for Biomedical Sciences, University of Copenhagen, Denmark) for GLP-1 measurements and J. Bach (Department for Biomedical Sciences, University of Copenhagen, Denmark) for NEFA and glycerol measurements.

Data availability

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Funding

The clinical studies were conducted at Center for Diabetes Research (Gentofte Hospital, Denmark) and the in vitro studies at Department of Biomedical Sciences (University of Copenhagen, Denmark), which were supported by Gangstedfonden, the European Foundation for the Study of Diabetes, and Aase og Ejnar Danielsens fond.

Duality of interest

GIP(3-30)NH2 as a therapeutic agent is protected by intellectual property rights owned by University of Copenhagen (PCT/DK2015/050266). AHS, MBC, FKK, MMR, JJH, LSG, and MBNG are co-founders of the company Antag Therapeutics ApS founded after the completion of the present study. TV has received lecture fees from, participated in advisory boards of, consulted for and/or received research grants from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, MSD/Merck, Novo Nordisk and Sanofi. FKK has received lecture fees from, participated in advisory boards of, consulted for and/or received research grants from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, MSD/Merck, Novo Nordisk, Sanofi and Zealand Pharma. Other authors declare that there is no duality of interest associated with their contribution to this manuscript.

Contribution statement

LSG, MBC, AHS, TV, MMR, JJH, and FKK designed the clinical study, and LSG and ARL performed the clinical study and data acquisition. LSG, AHS, MBNG and MMR designed the in vitro studies, and MBNG performed them. LSG and BH performed the RIA and ELISA measurements. BH was responsible for RIA and ELISA data acquisition and interpretation. FD was responsible for the NEFA and glycerol measurements, analyses and interpretation of data in general. LSG, MMR, MBC, and FKK performed the data analyses, wrote the manuscript and approved the final version. MBC, BH, ARL, AHS, MBNG, FD, TV and JJH edited the manuscript and approved the final version. LSG and FKK are the guarantors of the clinical part of the study, had full access to all of these data and take responsibility for the integrity of the data and accuracy of the data analysis. LSG and MMR are guarantors of the in vitro part of the study, had full access to all of these data and take responsibility for the integrity of the data and accuracy of the data analysis.

References

  1. 1.
    Sonne DP, Rehfeld JF, Holst JJ et al (2014) Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1. Eur J Endocrinol 171:407–419CrossRefPubMedGoogle Scholar
  2. 2.
    Kreymann B, Ghatei MA, Williams G, Bloom SR (1987) Glucagon-Like Peptide-1 7-36: a physiological incretin in man. Lancet 330:1300–1304CrossRefGoogle Scholar
  3. 3.
    Vilsbøll T, Krarup T, Madsbad S, Holst J (2002) Defective amplification of the late phase insulin response to glucose by gip in obese type ii diabetic patients. Diabetologia 45:1111–1119CrossRefPubMedGoogle Scholar
  4. 4.
    Cornell S (2012) Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes. J Clin Pharm Ther 37:510–524CrossRefPubMedGoogle Scholar
  5. 5.
    Eng J, Kleinman W, Singh L et al (1992) Isolation and characterization of exendin-4, an exendin-3 analogue, from heloderma suspectum venom. J Biol Chem 267:7402–7405PubMedGoogle Scholar
  6. 6.
    Schirra J, Sturm K, Leicht P et al (1998) Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J Clin Invest 101:1421–1430CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Edwards C, Todd J, Mahmoudi M et al (1999) Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 48:86–93CrossRefPubMedGoogle Scholar
  8. 8.
    Nauck MA, Heimesaat MM, Ørskov C et al (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301–307CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Krarup T (1988) Immunoreactive gastric inhibitory polypeptide. Endocr Rev 9:122–134CrossRefPubMedGoogle Scholar
  10. 10.
    Nissen A, Christensen M, Knop FK et al (2014) Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans. J Clin Endocrinol Metab 99:E2325–E2329CrossRefPubMedGoogle Scholar
  11. 11.
    Asmar M, Simonsen L, Arngrim N et al (2014) Glucose-dependent insulinotropic polypeptide has impaired effect on abdominal, subcutaneous adipose tissue metabolism in obese subjects. Int J Obes 38:259–265CrossRefGoogle Scholar
  12. 12.
    Asmar M, Simonsen L, Madsbad S et al (2010) Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans. Diabetes 59:2160–2163CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Koffert J, Honka H, Teuho J et al (2017) Effects of meal and incretins in the regulation of splanchnic blood flow. Endocr Connect 6:179–187CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Christensen M, Vedtofte L, Holst JJ et al (2011) Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 60:3103–3109CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Christensen M, Calanna S, Sparre-Ulrich AH et al (2015) Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes. Diabetes 64:72–78CrossRefPubMedGoogle Scholar
  16. 16.
    Sparre-Ulrich AH, Hansen LS, Svendsen B et al (2016) Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors. Br J Pharmacol 173:27–38CrossRefPubMedGoogle Scholar
  17. 17.
    Hansen LS, Sparre-Ulrich AH, Christensen M et al (2016) N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor. Br J Pharmacol 173:826–838CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Getty-Kaushik L, Song DH, Boylan MO et al (2006) Glucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and reesterification. Obesity (Silver Spring) 14:1124–1131CrossRefGoogle Scholar
  19. 19.
    Tseng CC, Kieffer TJ, Jarboe LA et al (1996) Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP): effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. J Clin Invest 98:2440–2445CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Gelling RW, Coy DH, Pederson RA et al (1997) GIP(6-30amide) contains the high affinity binding region of GIP and is a potent inhibitor of GIP1-42 action in vitro. Regul Pept 69:151–154CrossRefPubMedGoogle Scholar
  21. 21.
    Deacon CF, Plamboeck A, Rosenkilde MM et al (2006) GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations. Am J Physiol Endocrinol Metab 291:E468–E475CrossRefPubMedGoogle Scholar
  22. 22.
    Gault VA, O’Harte FPM, Harriott P, Flatt PR (2002) Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem Biophys Res Commun 290:1420–1426CrossRefPubMedGoogle Scholar
  23. 23.
    McClean PL, Irwin N, Cassidy RS et al (2007) GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am J Physiol Endocrinol Metab 293:E1746–E1755CrossRefPubMedGoogle Scholar
  24. 24.
    Ravn P, Madhurantakam C, Kunze S et al (2013) Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor. J Biol Chem 288:19760–19772CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Nakamura T, Tanimoto H, Mizuno Y et al (2012) Biological and functional characteristics of a novel low-molecular weight antagonist of glucose-dependent insulinotropic polypeptide receptor, SKL-14959, in vitro and in vivo. Diabetes Obes Metab 14:511–517CrossRefPubMedGoogle Scholar
  26. 26.
    Ugleholdt R, Poulsen MLH, Holst PJ et al (2006) Prohormone convertase 1/3 is essential for processing of the glucose-dependent insulinotropic polypeptide precursor. J Biol Chem 281:11050–11057CrossRefPubMedGoogle Scholar
  27. 27.
    Portela-Gomes GM, Grimelius L, Stridsberg M (2008) Prohormone convertases 1/3, 2, furin and protein 7B2 (Secretogranin V) in endocrine cells of the human pancreas. Regul Pept 146:117–124CrossRefPubMedGoogle Scholar
  28. 28.
    Fujita Y, Asadi A, Yang GK et al (2010) Differential processing of pro-glucose-dependent insulinotropic polypeptide in gut. Am J Physiol Gastrointest Liver Physiol 298:G608–G614CrossRefPubMedGoogle Scholar
  29. 29.
    Gallwitz B, Witt M, Folsch UR, Creutzfeldt WSW (1993) Binding specificity and signal transduction of receptors for glucagon-like peptide-1 (7–36) amide and gastric inhibitory polypeptide on RINm5F insulinoma cells. J Mol Endocrinol 10:259–268CrossRefPubMedGoogle Scholar
  30. 30.
    Ørskov C, Rabenhøj L, Wettergren A et al (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. Diabetes 43:535–539CrossRefPubMedGoogle Scholar
  31. 31.
    Lindgren O, Carr RD, Deacon CF et al (2011) Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. J Clin Endocrinol Metab 96:2519–2524CrossRefPubMedGoogle Scholar
  32. 32.
    Hilsted L, Holst JJ (1982) On the accuracy of radioimmunological determination of somatostatin in plasma. Regul Pept 4:13–31CrossRefPubMedGoogle Scholar
  33. 33.
    Holst JJ, Bersani M (1991) Assays for the peptide products of somatostatin gene expression. Methods Neurosci 5:3–22CrossRefGoogle Scholar
  34. 34.
    Kissow H, Hartmann B, Holst JJ et al (2012) Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. Regul Pept 179:91–100CrossRefPubMedGoogle Scholar
  35. 35.
    Hovorka R, Soons PA, Young MA (1996) ISEC: a program to calculate insulin secretion. Comput Methods Prog Biomed 50:253–264CrossRefGoogle Scholar
  36. 36.
    Kjems LL, Christiansen E, Vølund A et al (2000) Validation of methods for measurement of insulin secretion in humans in vivo. Diabetes 49:580–588CrossRefPubMedGoogle Scholar
  37. 37.
    Sparre-Ulrich AH, Gabe MN, Gasbjerg LS et al (2017) GIP(3–30)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release. Biochem Pharmacol 131:78–88CrossRefPubMedGoogle Scholar
  38. 38.
    Schirra J, Nicolaus M, Woerle HJ et al (2009) GLP-1 regulates gastroduodenal motility involving cholinergic pathways. Neurogastroenterol Motil 21:609–618CrossRefPubMedGoogle Scholar
  39. 39.
    Salehi M, Vahl TP, D’Alessio DA (2008) Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion. J Clin Endocrinol Metab 93:4909–4916CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Kielgast U, Holst JJ, Madsbad S (2011) Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual B -cell function. Diabetes 60:1599–1607CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Fredriksson R, Lagerström MC, Lundin L-G, Schiöth HB (2003) The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 63:1256–1272CrossRefPubMedGoogle Scholar
  42. 42.
    Al-Sabah S, Al-Fulaij M, Ahmed HA (2014) Selectivity of peptide ligands for the human incretin receptors expressed in HEK-293 cells. Eur J Pharmacol 741:311–315CrossRefPubMedGoogle Scholar
  43. 43.
    Brubaker PL, Drucker DJ (2002) Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Recept Channels 8:179–188CrossRefPubMedGoogle Scholar
  44. 44.
    Svane MS, Jørgensen NB, Bojsen-Møller KN, et al (2016) Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery. Int J Obes (Lond): 1–8Google Scholar
  45. 45.
    Steinert RE, Schirra J, Meyer-Gerspach AC et al (2014) Effect of glucagon-like peptide-1 receptor antagonism on appetite and food intake in healthy men 1 – 3. Am J Clin Nutr 100:514–523CrossRefPubMedGoogle Scholar
  46. 46.
    Hansen L, Hartmann B, Bisgaard T et al (2000) Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. Am J Physiol Endocrinol Metab 278:E1010–E1018CrossRefPubMedGoogle Scholar
  47. 47.
    Solloway MJ, Madjidi A, Gu C et al (2015) Glucagon Couples Hepatic Amino Acid Catabolism to mTOR-Dependent Regulation of α-Cell Mass. Cell Rep 12:495–510CrossRefPubMedGoogle Scholar
  48. 48.
    Asmar M, Asmar A, Simonsen L et al (2017) The gluco- and liporegulatory and the vasodilatory effects of glucose-dependent insulinotropic polypeptide (GIP) are abolished by an antagonist of the human GIP receptor. Diabetes 66:2363–2237CrossRefPubMedGoogle Scholar
  49. 49.
    Thondam SK, Daousi C, Wilding JPH et al (2017) Glucose-dependent Insulinotropic Polypeptide promotes lipid deposition in subcutaneous adipocytes in obese, type 2 diabetes patients: a maladaptive response. Am J Physiol Endocrinol Metab 1:224–233CrossRefGoogle Scholar
  50. 50.
    Irwin N, Gault V, Flatt PR (2010) Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer’s disease? Expert Opin Investig Drugs 19:1039–1048CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Lærke S. Gasbjerg
    • 1
    • 2
    • 3
  • Mikkel B. Christensen
    • 1
    • 4
    • 5
  • Bolette Hartmann
    • 2
    • 3
  • Amalie R. Lanng
    • 1
  • Alexander H. Sparre-Ulrich
    • 2
    • 3
  • Maria B. N. Gabe
    • 2
    • 3
  • Flemming Dela
    • 2
    • 6
  • Tina Vilsbøll
    • 1
    • 4
    • 7
  • Jens J. Holst
    • 2
    • 3
  • Mette M. Rosenkilde
    • 2
    • 3
  • Filip K. Knop
    • 1
    • 3
    • 4
  1. 1.Center for Diabetes Research, Gentofte HospitalUniversity of CopenhagenHellerupDenmark
  2. 2.Department of Biomedical Sciences, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
  3. 3.Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
  4. 4.Department of Clinical Medicine, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
  5. 5.Department of Clinical Pharmacology, Bispebjerg HospitalUniversity of CopenhagenCopenhagenDenmark
  6. 6.Department of Geriatrics, Bispebjerg HospitalUniversity of CopenhagenCopenhagenDenmark
  7. 7.Steno Diabetes Center CopenhagenUniversity of CopenhagenGentofteDenmark

Personalised recommendations